EP1178786A4 - Agents a stabilisation proteinique actifs pharmacologiquement; procedes de fabrication et methodes d'utilisation - Google Patents

Agents a stabilisation proteinique actifs pharmacologiquement; procedes de fabrication et methodes d'utilisation

Info

Publication number
EP1178786A4
EP1178786A4 EP00932669A EP00932669A EP1178786A4 EP 1178786 A4 EP1178786 A4 EP 1178786A4 EP 00932669 A EP00932669 A EP 00932669A EP 00932669 A EP00932669 A EP 00932669A EP 1178786 A4 EP1178786 A4 EP 1178786A4
Authority
EP
European Patent Office
Prior art keywords
methods
preparation
active agents
pharmacologically active
protein stabilized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP00932669A
Other languages
German (de)
English (en)
Other versions
EP1178786A1 (fr
Inventor
Neil P Desai
Chunlin Tao
Andrew Yang
Leslie Louie
Zhiwen Yao
Patrick Soon-Shiong
Shlomo Magdassi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abraxis Bioscience LLC
Original Assignee
American Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/316,642 external-priority patent/US6749868B1/en
Application filed by American Bioscience Inc filed Critical American Bioscience Inc
Publication of EP1178786A1 publication Critical patent/EP1178786A1/fr
Publication of EP1178786A4 publication Critical patent/EP1178786A4/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EP00932669A 1999-05-21 2000-05-19 Agents a stabilisation proteinique actifs pharmacologiquement; procedes de fabrication et methodes d'utilisation Ceased EP1178786A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US316642 1989-02-28
US09/316,642 US6749868B1 (en) 1993-02-22 1999-05-21 Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
PCT/US2000/013954 WO2000071079A2 (fr) 1999-05-21 2000-05-19 Agents a stabilisation proteinique actifs pharmacologiquement; procedes de fabrication et methodes d'utilisation

Publications (2)

Publication Number Publication Date
EP1178786A1 EP1178786A1 (fr) 2002-02-13
EP1178786A4 true EP1178786A4 (fr) 2006-03-01

Family

ID=23229970

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00932669A Ceased EP1178786A4 (fr) 1999-05-21 2000-05-19 Agents a stabilisation proteinique actifs pharmacologiquement; procedes de fabrication et methodes d'utilisation

Country Status (5)

Country Link
EP (1) EP1178786A4 (fr)
AU (3) AU784416B2 (fr)
CA (2) CA2371912C (fr)
HK (1) HK1045646A1 (fr)
WO (1) WO2000071079A2 (fr)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030199425A1 (en) * 1997-06-27 2003-10-23 Desai Neil P. Compositions and methods for treatment of hyperplasia
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
CA2389583A1 (fr) * 1999-10-27 2001-05-03 Baker Norton Pharmaceuticals, Inc. Methode et compositions pour administration orale de taxanes a des patients humains
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
BR0212833A (pt) 2001-09-26 2004-10-13 Baxter Int Preparação de nanopartìculas de tamanho submìcron através de dispersão e de remoção de solvente ou de fase lìquida
IL160927A0 (en) * 2001-10-15 2004-08-31 Crititech Inc Compositions and methods for delivery of poorly water soluble drugs and method of treatment
ITMI20020680A1 (it) * 2002-03-29 2003-09-29 Acs Dobfar Spa Composizione antitumorale migliorata a base di paclitaxel e metodo per il suo ottenimento
NZ518997A (en) * 2002-05-16 2004-12-24 Interag Injection formulation for parenteral administration of biodegradable implant for sustained release of active agent
SI21222A (sl) * 2002-05-28 2003-12-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Postopek za pripravo nanodelcev
GB0216700D0 (en) 2002-07-18 2002-08-28 Astrazeneca Ab Process
JP2006524632A (ja) 2002-12-09 2006-11-02 アメリカン バイオサイエンス、インコーポレイテッド 組成物及び薬物送達方法
GB0302673D0 (en) 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
IL160095A0 (en) * 2004-01-28 2004-06-20 Yissum Res Dev Co Formulations for poorly soluble drugs
WO2006073154A1 (fr) * 2005-01-07 2006-07-13 Eisai R&D Management Co., Ltd. Préparation thérapeutique et procédé d'élaboration de ladite préparation
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
KR101914254B1 (ko) 2005-02-18 2018-11-02 아브락시스 바이오사이언스, 엘엘씨 치료제의 조합 및 투여 방식, 및 조합 요법
MX2007015183A (es) * 2005-06-14 2008-02-19 Baxter Int Formulaciones farmaceuticas para minimizar las interacciones farmaco-farmaco.
EP2404594B1 (fr) * 2005-08-31 2017-12-20 Abraxis BioScience, LLC Compositions de docetaxel présentant une stabilité accrue
US20100166872A1 (en) * 2005-10-21 2010-07-01 Amarjit Singh Novel improved compositions for cancer therapy
JP5301995B2 (ja) * 2006-08-29 2013-09-25 富士フイルム株式会社 難水溶性化合物封入親水性マトリックスおよびその製法
US9675578B2 (en) 2006-12-14 2017-06-13 Abraxis Bioscience, Llc Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
DK2481402T3 (en) 2007-03-07 2018-08-06 Abraxis Bioscience Llc Nanoparticle comprising rapamycin and albumin as anticancer agent
ES2435452T3 (es) 2007-06-01 2013-12-19 Abraxis Bioscience, Llc Métodos y composiciones para tratar un cáncer recurrente
FR2924024B1 (fr) * 2007-11-27 2012-08-17 Centre Nat Rech Scient Nanoparticules d'actifs therapeutiques de faible solubilite aqueuse
KR20100048751A (ko) * 2008-10-31 2010-05-11 주식회사 동성바이오레인 스프레이 가능한 캡슐화된 기능성 미립자 조성물과 그 제조방법
AU2009319183B2 (en) * 2008-11-27 2014-06-05 B.R.A.I.N. Biotechnology Research And Information Network Ag Hydrophobins as surface active proteins as excipients in solid pharmaceutical formulations
JP5936112B2 (ja) 2009-02-11 2016-06-15 アルブミディクス アクティーゼルスカブ アルブミン変異体及び複合体
ME03596B (fr) 2009-04-15 2020-07-20 Abraxis Bioscience Llc Compositions de nanoparticules exemptes de prion, et procédés afférents
CA2776241A1 (fr) 2009-10-30 2011-05-05 Novozymes Biopharma Dk A/S Variants d'albumine
ES2675212T3 (es) 2010-03-26 2018-07-09 Abraxis Bioscience, Llc Métodos de tratamiento de carcinoma hepatocelular
MX2012011155A (es) 2010-03-29 2012-12-05 Abraxis Bioscience Llc Metodos para mejorar suministros de farmacos y efectividad de agentes terapeuticos.
DK2552415T3 (en) 2010-03-29 2016-11-28 Abraxis Bioscience Llc Methods for treating cancer
CN103140225A (zh) 2010-06-04 2013-06-05 阿布拉科斯生物科学有限公司 治疗胰腺癌的方法
DK2790675T3 (da) 2011-12-14 2019-09-09 Abraxis Bioscience Llc Anvendelse af polymerexcipienser til frysetørring eller frysning af partikler
EP3330283A3 (fr) 2012-03-16 2018-07-11 Albumedix A/S Variants d'albumine
EP2917233A1 (fr) 2012-11-08 2015-09-16 Novozymes Biopharma DK A/S Variants d'albumine
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
PT106738B (pt) * 2013-01-09 2015-06-08 Hovione Farmaciencia Sa Método para o controlo do fenómeno de degradação difusional de ostwald (ostwald ripening) no processamento de partículas de um ingrediente farmacêutico
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
WO2014125082A1 (fr) 2013-02-16 2014-08-21 Novozymes Biopharma Dk A/S Modèle pharmacocinétique animal
JP6349381B2 (ja) 2013-03-12 2018-06-27 アブラクシス バイオサイエンス， エルエルシー 肺がんを処置する方法
US9962373B2 (en) 2013-03-14 2018-05-08 Abraxis Bioscience, Llc Methods of treating bladder cancer
CN104548116A (zh) * 2013-10-11 2015-04-29 程树海 一种稳定的蛋白质载药微粒***制备方法
CN104434808A (zh) 2014-07-03 2015-03-25 石药集团中奇制药技术（石家庄）有限公司 一种治疗性纳米粒子及其制备方法
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
SG10202107198SA (en) 2015-06-29 2021-08-30 Abraxis Bioscience Llc Methods of treating epithelioid cell tumors
WO2017029407A1 (fr) 2015-08-20 2017-02-23 Albumedix A/S Variants de l'albumine et leurs conjugués
JP2020500306A (ja) 2016-11-04 2020-01-09 オーフス ウニベルシテット 新生児Ｆｃ受容体の過剰発現により特徴づけられる腫瘍の同定と治療
DE102016125666A1 (de) * 2016-12-23 2018-06-28 Michael Denck HSA-Galenik
CN110753541A (zh) * 2017-04-24 2020-02-04 Zy治疗公司 用于体内递送的药物组合物、基本上不溶于水的药理学活性剂的制备方法
JP2021528362A (ja) 2018-03-20 2021-10-21 アブラクシス バイオサイエンス， エルエルシー ｍＴＯＲ阻害剤およびアルブミンのナノ粒子の投与を介して中枢神経系障害を処置する方法
CN115003284A (zh) 2019-10-28 2022-09-02 阿布拉科斯生物科学有限公司 白蛋白和雷帕霉素的药物组合物
US20230025865A1 (en) * 2019-12-11 2023-01-26 The Regents Of The University Of Michigan COMPOSITIONS AND METHODS FOR SYSTEMIC DELIVERY OF Bcl-2 AND Bcl-xL ANTAGONISTS

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998014174A1 (fr) * 1996-10-01 1998-04-09 Vivorx Pharmaceuticals, Inc. Agents pharmaceutiquement actifs stabilises par proteine, procedes de preparation et procedes d'utilisation
WO1999000113A1 (fr) * 1997-06-27 1999-01-07 Vivorx Pharmaceuticals, Inc. Nouvelles formulations d'agents pharmacologiques, leurs procedes de preparation et d'utilisation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4671954A (en) * 1983-12-13 1987-06-09 University Of Florida Microspheres for incorporation of therapeutic substances and methods of preparation thereof
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998014174A1 (fr) * 1996-10-01 1998-04-09 Vivorx Pharmaceuticals, Inc. Agents pharmaceutiquement actifs stabilises par proteine, procedes de preparation et procedes d'utilisation
WO1999000113A1 (fr) * 1997-06-27 1999-01-07 Vivorx Pharmaceuticals, Inc. Nouvelles formulations d'agents pharmacologiques, leurs procedes de preparation et d'utilisation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of WO0071079A3 *
SOON-SHIONG ET AL: "Biologic delivery systems: from discovery to clinical application", 1998, PROCEEDINGS OF THE INTERNATIONAL SYMPOSIUM ON CONTROLLED RELEASE BIOACTIVE MATERIALS, PAGE(S) 103-104, ISSN: 1022-0178, XP002125685 *

Also Published As

Publication number Publication date
AU5035900A (en) 2000-12-12
AU2006202836B2 (en) 2009-10-08
AU2006202836A1 (en) 2006-07-27
CA2371912C (fr) 2010-02-16
AU784416B2 (en) 2006-03-30
HK1045646A1 (zh) 2002-12-06
CA2371912A1 (fr) 2000-11-30
WO2000071079A2 (fr) 2000-11-30
CA2684454A1 (fr) 2000-11-18
EP1178786A1 (fr) 2002-02-13
AU2009217409A1 (en) 2009-10-08
WO2000071079A3 (fr) 2008-03-27

Similar Documents

Publication Publication Date Title
EP1178786A4 (fr) Agents a stabilisation proteinique actifs pharmacologiquement; procedes de fabrication et methodes d'utilisation
HK1050367A1 (en) Pharmaceutically active compounds.
IL137346A0 (en) Pharmaceutically active morpholinol
HK1048999A1 (zh) 氮雜䓬吲衍生物，它們的製備和應用
HUP0402113A3 (en) 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity, preparation and use thereof
ZA200201509B (en) Pharmaceutically active sulfonamide derivatives.
IL150022A0 (en) Imidazo [1,3,5] triazinones and the use thereof
HK1040398A1 (en) Pyridopyranoazepine derivatives, preparation and therapeutic use
HUP0105039A3 (en) Fungicidal propargylether derivatives, preparation and use thereof
ZA200007415B (en) Amino acid derivatives and drugs containing the same as the active ingredient.
HK1031725A1 (en) 3-amino-3-arylpropan-1-ol-derivates, their preparation and their use
EP1210084A4 (fr) Pyridomorphinanes, thienomorphinanes et utilisation
HRP20040171A2 (en) Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof
AU2662799A (en) Modified pharmacologically active agents and improved therapeutic methods employing same
HUP0202377A2 (en) N-substituted perhydrodiazines, preparation and use thereof
ZA200110046B (en) Therapeutic agents.
EP1234834A4 (fr) Derives de 1,3,4-oxadiazoline-2-one et medicaments contenant ces derives utiles comme ingredient actif
SI1043306T1 (en) 3-amino-3-arylpropan-1-ol-derivates, their preparation and use
AU2001262699A1 (en) Biologically active agents and drugs
ZA989312B (en) Novel pharmaceutically active compounds, their preparation and use.
HUP0203678A3 (en) Nitro-sulfobenzamide-derivatives, preparation and use thereof
HUP0203455A3 (en) 2-arylquinoline derivatives, preparation and therautic use thereof
IL150237A0 (en) Benzophenone glycopyranosides, preparation and therapeutic use
AUPP899699A0 (en) Peptides, agents and methods
GB9801230D0 (en) Pharmaceutically active morpholinol

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20011130

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

D17D Deferred search report published (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20060117

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/00 20060101AFI20001204BHEP

Ipc: A61K 47/42 20060101ALI20060111BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ABRAXIS BIOSCIENCE, INC.

D17D Deferred search report published (deleted)
17Q First examination report despatched

Effective date: 20080502

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ABRAXIS BIOSCIENCE, LLC

APBK Appeal reference recorded

Free format text: ORIGINAL CODE: EPIDOSNREFNE

APBN Date of receipt of notice of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA2E

APBR Date of receipt of statement of grounds of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA3E

APAF Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ABRAXIS BIOSCIENCE, LLC

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

APBT Appeal procedure closed

Free format text: ORIGINAL CODE: EPIDOSNNOA9E

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20130131

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1045646

Country of ref document: HK